VALIRX PLC

• ◆

  Material uncertainty over going concern

  The Board has referred to the fact that the Group and Parent Company are reliant on future fund raisings to continue their activities as budgeted. Should future fund raisings be unsuccessful, this may cast significant doubt on the Group and parent Company's ability to continue as a going concern.

• ·

  Going-concern uncertainty disclosed

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.

1. VALIRX PLC 2006-10-03 → present
2. AZURE HOLDINGS PLC 2003-11-27 → 2006-10-03
3. ROOM SERVICE GROUP PLC 2002-01-08 → 2003-11-27
4. THE CUBE8 GROUP PLC 2001-06-14 → 2002-01-08
5. CUBE8.COM PLC 2000-01-26 → 2001-06-14

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

Adler Shine LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“The Board has referred to the fact that the Group and Parent Company are reliant on future fund raisings to continue their activities as budgeted. Should future fund raisings be unsuccessful, this may cast significant doubt on the Group and parent Company's ability to continue as a going concern.”

Group structure

1. VALIRX PLC · parent
   1. ValiPharma Limited 100% · England & Wales · Therapeutic research & development
   2. ValiSeek Limited 55.55% · England & Wales · Therapeutic research & development
   3. Cytolytix Limited 60% · England & Wales · Therapeutic research & development
   4. Inaphaea BioLabs Limited 100% · England & Wales · Preclinical and drug discovery testing
   5. Blue Ribbon Bio Limited · England & Wales · Development of ValiRx Group assets in Prostate Cancer
   6. ValiRx Animal Health Limited · England & Wales · Development of ValiRx group Assets for companion animal applications
   7. ValiRx Bioinnovation Limited 100% · England & Wales · Intermediate holding company
   8. Valisrc Limited 100% · England & Wales · Dormant

Significant events

• “ValiRx terminated the Letter of Intent with TheoremRx after they elected not to proceed with an agreed amendment to return the territory of Taiwan and maintain exclusivity in exchange for a $200,000 payment.”
• “VAL201 was deemed to still have strong clinical relevance within the treatment pathway for prostate cancer under the new, stricter evaluation criteria, including its potential in addressing resistance to hormone therapies.”
• “In January 2026, the Company entered into an Evaluation agreement with Royal Institute for the Advancement of Learning/McGill University, a Canadian based University, and the Institute for Research in Immunology and Cancer - Commercialization of Research, a Canadian non-profit organisation four months ahead of schedule.”
• “In May 2026, the Company raised approximately £1,155,000, before expenses, through a placing, subscription and retail offer of 577,500,000 new ordinary shares of 0.1 pence each at a price of 0.2 pence per share.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

9

last 12 months

Capital events

4

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.